Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Top-line results expected in 2Q 2021

Published: Jan 14, 2021
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) --
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment (n=45) in its pilot clinical study evaluating the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (“pMDI”) formulation in U.S. patients hospitalized with COVID-19.
David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, said: “Completing enrollment of the pilot study in COVID-19 is an important milestone and we are on track to report top-line results in the second quarter of 2021. We are pleased vaccines are now approved for the prevention of COVID-19; however, a significant unmet need remains for effective treatments for symptomatic patients. We believe ensifentrine, with its novel mechanism of action, could help to improve COVID-19 patient outcomes.”

Related Keywords

London , City Of , United Kingdom , Kimberly Minarovich Michael Barron , David Zaccardelli , Verona Pharma , Strategic Communications , International Media , Nasdaq , University Of Alabama At Birmingham , Lancet Respir Med , European Investor Enquiries , Eva Haas , Chronic Obstructive Pulmonary Disease , Registration Statement , Resume , Careers , Verona Pharma Completes Enrollment In Pilot Study Of Pmdi Ensifentrine Us Patients Hospitalized With Covid 19top Line Results Expected 2q 2021 , Biospace , Advice , லண்டன் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , வெரோனா பார்மா , மூலோபாய தகவல்தொடர்புகள் , சர்வதேச மீடியா , நாஸ்டாக் , பல்கலைக்கழகம் ஆஃப் அலபாமா இல் பர்மிங்காம் , ஐரோப்பிய முதலீட்டாளர் விசாரணைகள் , ஈவா ஹாஸ் , நாள்பட்ட தடைசெய்யும் நுரையீரல் நோய் , பதிவு அறிக்கை , தற்குறிப்பு , தொழில் ,